Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has established a Nomination Committee to regulate the appointment of directors and senior management, aiming to optimize the board’s composition and improve corporate governance. This move is expected to enhance the company’s strategic alignment and operational efficiency, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and production of innovative drugs and therapies. The company is committed to enhancing its corporate governance structure and optimizing its board and senior management composition.
Average Trading Volume: 906,033
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.89B
See more insights into 6990 stock on TipRanks’ Stock Analysis page.